Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Brian Lian, CEO, Viking Therapeutics: Great ... And then finally we have an amylin agonist that’s a little earlier. We plan to file an IND with this program later this year.

About Viking Therapeutics, Inc. Viking Therapeutics ... newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment ...

Viking Therapeutics' VENTURE-Oral study of VK2735 ... is developing MET-097i (a GLP-1 receptor agonist) and MET-233i (an amylin analog), both of which allow monthly dosing. MTSR is running the ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable ... application to begin clinical studies on its novel dual amylin and calcitonin receptor agonist (DACRA) for obesity ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Viking Therapeutics (NASDAQ ... The company is also conducting preclinical studies on a series of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic disorders ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to the need for ongoing management of patients on GLP-1s, an obesity expert ...